Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

DIAGNOSTIC TESTING OF HLA-DQ IN CELIAC DISEASE (CROSBI ID 684207)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Štingl Janković, Katarina ; Sviličić, Danijela ; Maskalan, Marija ; Burek Kamenarić, Marija ; Žunec, Renata ; Grubić, Zorana DIAGNOSTIC TESTING OF HLA-DQ IN CELIAC DISEASE // HLA / Marsh, Steven GE (ur.). 2018. str. 465-465 doi: 10.1111/tan.13251

Podaci o odgovornosti

Štingl Janković, Katarina ; Sviličić, Danijela ; Maskalan, Marija ; Burek Kamenarić, Marija ; Žunec, Renata ; Grubić, Zorana

engleski

DIAGNOSTIC TESTING OF HLA-DQ IN CELIAC DISEASE

The association of celiac disease (CD) and HLA class II genes is one of the best established and most documented disease associations of HLA system. The aim of our retrospective study was to determine whether there is a difference in HLA class II allele distribution among individuals who have a higher risk of developing CD (family members of confirmed CD patients or individuals with unconfirmed diagnosis who were referred to our Tissue Typing Centre for HLA typing as a part of the diagnostic procedure) and healthy controls with no history of CD in their family background. For that purpose, we analyzed the results of HLADQ typing performed using the PCR-SSP high resolution method (Olerup GmbH, Vienna, Austria) carried out for patients with CD (N=118), family members of CD patients (N=206), subjects with unconfirmed CD (N=1685) and healthy controls (HC) (N=985). Results show that genotype DQ2.5 cis in both single or double dose was statistically more frequent among all the groups when compared with HC (P<0.0001, each). Also, it was more frequent among patients with CD than family members (P<0.0001 both single and double dose) and unconfirmed patients (P=0.0003 and P=0.0057, respectively). The trans configuration of this genotype also showed significantly higher incidence among patients when compared with HC, but also unconfirmed patients and family members (P=0.0002, P=0.0032 and P=0.0160, respectively). No difference was seen between unconfirmed patients and family members when compared with controls. The DQ8 genotype did not show this specific pattern. No statistical significance was observed in any of the groups both for single or double doses. These results show that the highest risk for CD was indicated by the presence of the HLA-DQ2.5 heterodimer (HLA-DQA1*05- DQB1*02) both in single or double dose combination for all CD patients and underline the importance of HLADQB1 typing for assessing the susceptibility to CD.

HLA-DQ, celic disease

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

465-465.

2018.

nije evidentirano

objavljeno

10.1111/tan.13251

Podaci o matičnoj publikaciji

HLA

Marsh, Steven GE

2059-2310

Podaci o skupu

32nd European Immunogenetics and Histocompatibility Conference (EFI) ; 25th Annual Meeting of the Italian Society for Immunogenetics and Transplantation Biology (AIBT)

poster

09.05.2018-12.05.2018

Venecija, Italija; Lido, Italija

Povezanost rada

Biologija, Kliničke medicinske znanosti

Poveznice
Indeksiranost